Parasites of the genus Leishmania cause a variety of devastating and often fatal diseases in humans worldwide. Because a vaccine is not available and the currently small number of existing drugs are less than ideal due to lack of specificity and emerging drug resistance, the need for new therapeutic strategies is urgent. Natural products and their derivatives are being used and explored as therapeutics and interest in developing such products as antileishmanials is high. The enzyme arginase, the first enzyme of the polyamine biosynthetic pathway in Leishmania, has emerged as a potential therapeutic target. The flavonols quercetin and fisetin, green tea flavanols such as catechin (C), epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin-3-gallate (EGCG), and cinnamic acid derivates such as caffeic acid inhibit the leishmanial enzyme and modulate the host’s immune response toward parasite defense while showing little toxicity to the host. Quercetin, EGCG, gallic acid, caffeic acid, and rosmarinic acid have proven to be effective against Leishmania in rodent infectivity studies. Here, we review research on these natural products with a focus on their promise for the development of treatment strategies as well as unique structural and pharmacokinetic/pharmacodynamic features of the most promising agents.

Parasites of the genus Leishmania cause a variety of devastating and often fatal diseases in humans and domestic animals worldwide. The need for new therapeutic strategies is urgent because no vaccine is available, and treatment options are limited due to a lack of specificity and the emergence of drug resistance. Polyamines are metabolites that play a central role in rapidly proliferating cells, and recent studies have highlighted their critical nature in Leishmania. Numerous studies using a variety of inhibitors as well as gene deletion mutants have elucidated the pathway and routes of transport, revealing unique aspects of polyamine metabolism in Leishmania parasites. These studies have also shed light on the significance of polyamines for parasite proliferation, infectivity, and host–parasite interactions. This comprehensive review article focuses on the main polyamine biosynthetic enzymes: ornithine decarboxylase, S-adenosylmethionine decarboxylase, and spermidine synthase, and it emphasizes recent discoveries that advance these enzymes as potential therapeutic targets against Leishmania parasites.

The polyamine pathway in Leishmania parasites has emerged as a promising target for therapeutic intervention, yet the functions of polyamines in parasites remain largely unexplored. Ornithine decarboxylase (ODC) and spermidine synthase (SPDSYN) catalyze the sequential conversion of ornithine to putrescine and spermidine. We previously found that Leishmania donovani Δodc and Δspdsyn mutants exhibit markedly reduced growth in vitro and diminished infectivity in mice, with the effect being most pronounced in putrescine-depleted Δodc mutants. Here, we report that, in polyamine-free media, ∆odc mutants arrested proliferation and replication, while ∆spdsyn mutants showed a slow growth and replication phenotype. Starved ∆odc parasites also exhibited a marked reduction in metabolism, which was not observed in the starved ∆spdsyn cells. In contrast, both mutants displayed mitochondrial membrane hyperpolarization. Hallmarks of apoptosis, specifically DNA fragmentation and membrane modifications, were observed in Δodc mutants incubated in polyamine-free media. These results show that putrescine depletion had an immediate detrimental effect on cell growth, replication, and mitochondrial metabolism and caused an apoptosis-like death phenotype. Our findings establish ODC as the most promising therapeutic target within the polyamine biosynthetic pathway for treating leishmaniasis.

The genus Leishmania consists of over 20 different species causing a spectrum of disease symptoms categorized as cutaneous, mucocutaneous, or visceral leishmaniasis. No vaccine is available in humans, and current drug regimens suffer from low efficacy, associated toxicities, and are increasingly becoming side-lined by drug resistance. Because of this, the development of new therapeutics is desperately needed. Recent years, the therapeutic use of nanotechnology has increased exponentially. The biogenic synthesis of these nanostructures creates particles similar to those chemically synthesized but are often more environmentally safe, cost-effective, and allow for increased control over size, shape, and composition. Here, we provided a review of the current publications using the biogenic synthesis of nanoparticles particularly focusing on those used in the treatment of leishmaniasis published from January 1, 2010, to April 30, 2025. The documents were analyzed by applying criteria such as nanometal type, source of green synthesis (plant or microorganism), nanoparticles size, Leishmania species (sp.) and stage (promastigote or amastigote), cytotoxicity, and in vivo studies. A total of 50 articles were analyzed. Among biogenic nanoparticles (NPs), silver NPs were the most extensively studied (15 studies), while Leishmania tropica (L. tropica) was the most frequently investigated sp. Plant material was the most sources starting material for green synthesis. Produced NPs’ size varied between 2 and 500 nm. Regarding the effect of NPs on Leishmania parasites, most were done in vitro, and only 5 in vivo studies (10%) reported. Moreover, leishmanicidal effects were reported via oxidative stress, mainly through production of reactive oxygen species and nitrogen radical species. In general, green synthesis produced NPs with smaller sizes, larger surface area to volume ratios, and better internalization by the cells. Thus, green synthesis of NPs could be a promising option to resolve current treatment safety and efficacy concerns while also maintaining accessibility in low- and middle-income countries.

Mammalian cells tightly regulate the shift between catabolism and anabolism to maintain energy homeostasis during starvation. Among other adaptations, cells adapt to nutrient restriction by downregulating translation, the most energy consuming cellular process, and inducing autophagy. Polyamines are ubiquitous small polycationic endogenous metabolites indispensable for cellular growth and viability. They regulate both autophagy and translation processes, coordinating an intriguing metabolic hub during cellular adaptation to starvation. Recent studies have highlighted a complex role for polyamines during starvation and a growing body of evidence underscores various nutrients and nutrient-sensing pathways that modulate autophagy through their influence on the mammalian target of rapamycin complex 1 (mTORC1) signaling. mTORC1 is a master regulator of cellular anabolism, including translation. Less explored is how these coordinated systems adapt and respond to starvation. This scoping review explores how changes in polyamine metabolism and related molecules orchestrate the adaptive crosstalk between autophagy, mTORC1, and translation to ensure that the mammalian cell conserves energy to maintain essential cellular functions during starvation. Our review highlights that spermidine and one of its major cellular targets, translation initiation factor 5A (eIF5A), facilitate translation of transcription factor EB (TFEB) to induce autophagy during starvation. Starvation suppresses mTORC1 activity, leading to reduced ribosome biogenesis and translation while promoting autophagy to meet cellular energy demands. We discuss the adaptive mechanisms by which reduced levels of acetyl-CoA, amino acids, EP300, glucose, insulin, and S-adenosylmethionine inhibit mTORC1 and simultaneously induce autophagy. Additionally, we describe the adaptive role that glucagon, Sestrin2, and urea play to inhibit mTORC1 and how eIF5A, glucagon, spermidine, and TFEB induce autophagy.

The polyamine pathway in Leishmania parasites has emerged as a promising target for therapeutic intervention, yet the functions of polyamines in parasites remain largely unexplored. Ornithine decarboxylase (ODC) and spermidine synthase (SPDSYN) catalyze the sequential conversion of ornithine to putrescine and spermidine. We previously described that Leishmania donovani Δodc and Δspdsyn mutants exhibit markedly reduced growth in vitro and diminished infectivity in mice, with the effect being most pronounced in putrescine-depleted Δodc mutants. Here, we report that in polyamine-free media, ∆odc mutants arrested proliferation and replication, while ∆spdsyn mutants showed a slow growth and replication phenotype. Starved ∆odc parasites also exhibited a marked reduction in metabolism, which was not observed in the starved ∆spdsyn cells. In contrast, both mutants displayed mitochondrial membrane hyperpolarization. Hallmarks of apoptosis, DNA fragmentation and membrane modifications, were observed in Δodc mutants incubated in polyamine-free media. These results show that putrescine depletion had an immediate detrimental effect on cell growth, replication, and mitochondrial metabolism and caused an apoptosis-like death phenotype. Our findings establish ODC as the most promising therapeutic target within the polyamine biosynthetic pathway for treating leishmaniasis.